by The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 Bn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Biopharma buffers play a vital role in maintaining optimal pH during various biopharmaceutical manufacturing and purification processes. Products like recombinant proteins, monoclonal antibodies, and vaccines require controlled pH environments during manufacturing and purification to maintain their stability, efficacy, and safety. Changing pH can disrupt protein structure and impede their functional properties.
Market Overview:
Biopharma buffers are solutions used to maintain optimal pH during biopharmaceutical manufacturing. Common types include acetate, citrate, phosphate, and Tris buffers. They help control pH for processes like cell cultivation, purification, formulation, and storage of biologics. Maintaining precise pH is critical to preserving the effectiveness of products like vaccines, blood factors, and monoclonal antibodies.
Market key trends:
One key trend in the Global Biopharma Buffer Market is the rise of plant-based proteins. As consumer demand for sustainable and vegan alternatives grows, biopharma companies are investing in plants as production systems. Developing plant-based versions of biologics such as antibodies requires optimized buffer conditions to prevent degradation during extraction and purification. Plant cell toxicity is also a concern, necessitating stringent pH control throughout manufacturing. This is driving greater adoption of high-performance biopharma buffers tailored for plant-based biologics.
Segment Analysis
The global biopharma buffer market is segmented on the basis of type, end user and geography. By type, the market is classified into phosphate buffer, tris buffer, acetate buffer and other buffers. Among these, the phosphate buffer segment dominated the market in 2022 due to its wide usage in DNA and RNA purification, ELISA assays, cell lysis and nucleic acid precipitation techniques. It is one of the most common buffer used in biologics manufacturing.
Key Takeaways
The global biopharma buffer market is expected to witness high growth, exhibiting CAGR of 7.1% over the forecast period, due to increasing research activities in biologics manufacturing.
Regional analysis: North America accounted for the largest share of the global biopharma buffer market in 2022 due to presence of large number of key biopharma companies and rising research in drug discovery and development in the region.
Key players: Key players operating in the biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., Sartorius AG, Corning Inc., Becton, Dickinson and Company, GE Healthcare, Promega Corporation. Merck KGaA holds the leading position due to its broad product portfolio and strong geographic presence across major markets.
The global biopharma buffer market size was valued at US$ 3.68 Bn in 2023 and is expected to reach US$ 7.93 Bn by 2030, expanding at a CAGR of 7.1% during the forecast period.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
